Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.

doi:10.1021/jm0009181

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.

Journal of medicinal chemistry - 13 Jul 2000

Yuthavong Y, Vilaivan T, Chareonsethakul N, Kamchonwongpaisan S, Sirawaraporn W, Quarrell R, Lowe G

Abstract excerpt

The Ala16Val+Ser108Thr (A16V+S108T) mutant of the Plasmodium falciparum dihydrofolate reductase (DHFR) is a key mutant responsible for cycloguanil-resistant malaria due to steric interaction between Val-16 and one of the C-2 methyl groups of cycloguanil. 4,6-Diamino-1,2-dihydrotriazines have been prepared, in which both methyl groups of cycloguanil are replaced by H or by H and an alkyl or phenyl group, and their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Drug Resistance
Share to Folic Acid Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Plasmodium falciparum

Share to Proguanil

Share to Structure-Activity Relationship

Share to Tetrahydrofolate Dehydrogenase

Share to Triazines

Source

Open in PubMed

Identifiers

PMID: 10893311
DOI: 10.1021/jm0009181

Genes

DHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.